Conditions: Liver Cirrhosis
Keywords: conivaptan Liver Cirrhosis Hypertension, Portal
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 20
Healthy volunteers: no

Brief summary:
To evaluate the safety of IV conivaptan in stable euvolemic or hypervolemic cirrhotic patients, and to characterize the effects of IV conivaptan on the hepatic hemodynamic response in patients with cirrhosis.

Detailed description:

Arms:
arm 1: Conivaptan intravenous loading dose (10 mg) + 2.5 mg continuous infusion over 6.5 hours arm 2: Conivaptan intravenous loading dose (20 mg) + 5 mg continuous infusion over 6.5 hours arm 3: Placebo continuous intravenous infusion over 6.5 hours

Interventions: intervention 1: conivaptan intervention 2: Placebo
Intervention descriptions: intervention 1: IV intervention 2: IV

Protocol document: